National Gaucher Foundation - Gaucher Disease
Slideshow Image 1
Slideshow Image 2
Slideshow Image 3

Pfizer

About Gaucher Personal Supportâ„¢ (GPS)

Overview
GPS (Gaucher Personal Support™) is a specialized support program for people with Gaucher disease taking ELELYSO™ (taliglucerase alfa) for injection. ELELYSO is an enzyme replacement therapy for adults with a confirmed diagnosis of Type 1 Gaucher disease.

GPS delivers individualized support and service to people living with Gaucher disease, their health care providers, and payers by offering personalized help through one telephone number. GPS was designed to provide a positive patient experience by offering patient-centered care. Pfizer’s commercial expertise and infrastructure was leveraged to develop this specialized support program that was built from the ground up by listening to the needs of people with Gaucher disease, their advocates, and physicians.

Key GPS Features
GPS staffs a dedicated team of health care specialists who are available 24/7 to help people living with Gaucher disease and their families with a suite of services, including reimbursement assistance, help with locating infusion services, and ongoing pharmacy support.

GPS also includes a specialty pharmacy that is the sole provider of ELELYSO.

  • The GPS Case Manager is one of the core elements of this program. When a patient begins treatment with ELELYSO, he or she is connected with a case manager who becomes that person’s primary contact to coordinate his or her personalized support through GPS.
  • GPS Case Managers and a team of both medical and non-medical professionals are all accessible through the same phone number. The case manager can help with many Gaucher disease and disease-related issues by working on behalf of the patient with fully trained and capable reimbursement specialists, nurses, and pharmacists.

Reimbursement Support
GPS offers reimbursement support services for people who may need assistance paying for ELELYSO. GPS features an assistance program for insured, uninsured, and underinsured patients. Most patients will be eligible for $0 out-of-pocket costs for ELELYSO.* ELELYSO and supplies are available at no cost to qualified uninsured and underinsured patients. The GPS Case Manager can help find sources of reimbursement assistance through which a patient may qualify. For more information about specific patient qualifications, please see page 3 or call 1-855-ELELYSO (1-855-353-5976).

___________________________
*ELELYSO $0 Co-pay Card Terms and Conditions apply. See page 3 for full Terms and Conditions.
This program is not health insurance
The co-pay program is available only through the Gaucher Personal Support program
• For any questions, please call Gaucher Personal Support at 1-855-ELELYSO (1-855-353-5976). Gaucher Personal Support, 17877 Chesterfield Airport Road, Chesterfield, MO 63005
• No membership fees required. Average co-pay savings per patient per year is $2,000. The maximum limit is $10,000 per year or the amount of the co-pay you paid, whichever is less

Please see full Prescribing Information enclosed.

Infusion Support
The Case Manager also helps people taking ELELYSO coordinate infusion services. He or she may be able to help arrange home nursing support (with insurance and physician approval), help schedule transportation to and from infusions, and aid in coordinating infusions while traveling.

Ongoing Support
In addition to the Case Manager, as part of the GPS program, registered nurse clinicians and pharmacists are on call 24/7. A Patient Affairs Liaison is also available to assist people living with Gaucher disease and family members with general questions about GPS and Pfizer.

For more information about ELELYSO, patients can visit www.ELELYSO.com or call 1-855-ELELYSO (1-855-353-5976) for a free patient information kit about ELELYSO and the GPS program. Physicians may visit www.ELELYSOHCP.com or call 1-855-ELELYSO (1-855-353-5976).

Important Safety Information
As with any intravenous protein medicine, like enzyme replacement therapy (ERT), severe allergic reactions (including anaphylaxis) have been observed in patients treated with ELELYSO. If this occurs, your doctor may immediately discontinue ELELYSO. Patients who have experienced anaphylaxis to ELELYSO or another ERT should proceed with caution upon retreatment.

In addition, infusion reactions (including allergic reactions) – defined as a reaction occurring within 24 hours of the infusion – were the most commonly observed reactions to ELELYSO. The most commonly observed infusion reactions were headache, chest pain or discomfort, weakness, fatigue, hives, abnormal redness of the skin, increased blood pressure, back or joint pain, and flushing. Most of these reactions were mild and did not require treatment.

Management of infusion reactions is based on the type and severity of the reaction. Your doctor may manage infusion reactions by temporarily stopping the infusion, slowing the infusion rate, or treating with medications such as an antihistamine and/or a fever reducer. Treatment with antihistamines and/or corticosteroids prior to infusion with ELELYSO may prevent these reactions.

Other common adverse reactions observed were upper respiratory tract infections, throat infection, flu, urinary tract infection, and pain in extremities.

As with all therapeutic proteins, including ERTs, there is a possibility of developing antibodies to ELELYSO. However, it is currently unclear whether this has an impact on the clinical response or adverse reactions. Patients with an immune response to other ERTs who are switching to ELELYSO should continue to be monitored for antibodies. Comparison of the frequency of antibodies across ERTs may be misleading.

If you are pregnant, or plan to become pregnant, you should talk to your doctor about potential benefits and risks.

Please see full Prescribing Information enclosed.

Terms and Conditions
By using the co-pay program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

1. This co-pay program is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare or other federal or state healthcare programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico [formerly known as “La Reforma de Salud”]).
2. This co-pay program is not valid for prescriptions that are eligible to be reimbursed by private insurance plans or other health or pharmacy benefit programs which reimburse you for the entire cost of your prescription drugs.
3. 100% of prescription co-pays will be covered for majority of patients. Average co-pay savings is $2,000 per year. The maximum limit is $10,000 per year or the amount of the co-pay you paid, whichever is less.
4. You must deduct the value received under this program from any reimbursement request submitted to your insurance plan, either directly by you or on your behalf.
5. This co-pay program is not valid for Massachusetts residents whose prescriptions are covered in whole or in part by third party insurance, or where otherwise prohibited by law.
6. Cannot be combined with any other rebate/coupon, free trial or similar offer for the specified prescription.
7. This program is not health insurance.
8. The co-pay program is available only through the Gaucher Personal Support program. For any questions, please contact Gaucher Personal Support at 1-855-ELELYSO (1-855-353-5976). Gaucher Personal Support, 17877 Chesterfield Airport Road, Chesterfield, MO 63005.
9. Offer good only in the US and Puerto Rico.
10. Pfizer reserves the right to rescind, revoke or amend the program without notice.
11. This co-pay program expires 12/31/2013.

Please see full Prescribing Information enclosed.